Johnson & Johnson to Provide Latest Updates on Hepatitis C Treatment

Pierre Raboisson, Head of Medicinal Chemistry at Janssen, to make a keynote address at 16th annual Superbugs and Superdrugs summit

LONDON , UNITED KINGDOM, February 11, 2014 /EINPresswire.com/ -- SMi are pleased to announce that Pierre Raboisson, Head of Medicinal Chemistry at Janssen (Johnson & Johnson), will be making a keynote address at the industry established conference on Superbugs & Superdrugs taking place soon on 5th and 6th March in London, UK.

In recent months, The FDA approved a new drug from Johnson & Johnson (Olysio) for use in treating chronic hepatitis C infections. Currently more than 170 million people are estimated to be infected with the virus. Following on from this, Janssen’s Head of Medicinal Chemistry will be presenting attendees with a keynote address entitled: The Latest Treatment for Hepatitis C, Challenges and Opportunities. Highlights will include:

• Diseases leading from chronic HCV
• Protease Inhibitor (boceprevir, telaprevir and semprevir) based triple therapy with pegylated interferon and ribavirin
• New direct-acting antivirals
• Updates on interferon-free combination treatment regimens

Visit http www.superbugsuperdrugs.com to view presentation details and the full speaker line-up for 2014

The 16th annual conference on Superbugs & Superdrugs is the focal point for everyone working in the market for infectious diseases. Attending provides a unique forum to engage with leading industry experts active in the field. With less than a month until the event takes place, those interested in attending can book online at www.superbugsuperdrugs.com

Superbugs & Superdrugs will aim to provide attendees tools in:

• Best Practices – Share ideas with industry leaders to identify cutting-edge developments including antibody based strategies as a new method to tackle antimicrobial resistance , pre-clinical developments and new treatments for infection and preventing infection
• Strategy – Aid your antibiotic drug research and hear case study driven presentations from leading pharmaceutical and regulatory KOLS including EFPIA, GSK, BARDA, the European Commission, Johnson & Johnson, Sanofi, Medlmmune and Astellas
• Funding - Discover the latest Public/Private Partnerships to combat antimicrobial resistance both in the US and in Europe
• Industry - Learn about hot topics which include antimicrobial stewardship, nanoparticulate oligonucleotide antibacterials and alternative models for tackling antimicrobial resistance
• Join the Debate – Participate in a round table discussion led by the European Commission, EFPIA, BARDA, GSK and TranScrip partners on Antibiotic R&D funding.
• The Future - Look ahead into the European Antibiotic Recovery Plan and analyse global solutions.
• Peer to peer networking - Ample opportunity for discussion, including 2 morning coffee breaks, 2 networking lunches and 2 afternoon tea sessions. Make new contacts, meet old friends and immerse yourself in a universe of new insights.

Previous instalments in the Superbugs & Superdrugs series received positive feedback from the industry including:

"Very well organised conference." – GSK
"Good level of quality." – Janssen
"Very good and engaging speakers." – Merck
"Good topics, mix of research, clinical development and perspectives" - J&J

For further information visit www.superbugsuperdrugs.com

Superbugs and Superdrugs: A focus on antibacterials
5th & 6th March 2014
Holiday Inn Regents Park, London UK
www.superbugsuperdrugs.com

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here